More youths with type 1 diabetes meet time-in-range goal wit
The percentage of youths with type 1 diabetes spending at least 70% time in range more than doubled after 3 months of using a hybrid closed-loop insulin delivery system, according to a study published in Diabetes Technology & Therapeutics.

This study aimed to describe real-world outcomes for youth using the Tandem t:slim X2 insulin pump with Control-IQ technology (“Control-IQ”) for 6 months at a large pediatric clinic.

Youth with type 1 diabetes, who started Control-IQ for routine care, were prospectively followed. Data on system use and glycemic control were collected before Control-IQ start, and at 1, 3, and 6 months after start. Mixed models assessed change across time; interactions with baseline hemoglobin A1c (HbA1c) and age were tested.

-- In 191 youth (median age 14, 47% female, and median HbA1c 7.6%), percent time with glucose levels 70–180?mg/dL (time-in-range [TIR]) improved from 57% at baseline to 66% at 6 months.

-- The proportion of participants reaching TIR target (>70%) doubled from 23.5% at baseline to 47.8% at 3 months, sustaining at 46.7% at 6 months.

-- Glucose management indicator (approximation of HbA1c) improved from 7.5% at baseline to 7.1% at 3 months and 7.2% at 6 months.

-- Those with higher baseline HbA1c experienced the most substantial improvements in glycemic control.

-- Percent time using the Control-IQ feature was 86.4% at 6 months, and less than 4% of cohort discontinued use.

Conclusively, the Control-IQ system clinically and significantly improved glycemic control in a large sample of youth. System use was high at 6 months, with only a small proportion discontinuing use, indicating potential for sustaining results long term.